Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 25, 2016 - Issue 1
Submit an article Journal homepage
1,294
Views
13
CrossRef citations to date
0
Altmetric
Reviews

An overview of investigational new drugs for treating ankylosing spondylitis

Daniel WendlingRheumatology, Université de Franche-Comté, Besançon, France;Department of Rheumatology, University Teaching Hospital, CHRU de Besançon, Besançon, F–25030Besançon, FranceCorrespondence[email protected]
, MD, PhD
Pages 95-104 | Published online: 25 Nov 2015

Bibliography

  • Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
  • Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377(9783):2127–2137.
  • Wendling D, Claudepierre P, Prati C. Early diagnosis and management are crucial in spondyloarthritis. Joint Bone Spine. 2013;80(6):582–585.
  • Claudepierre P, Wendling D, Breban M, et al. Ankylosingspondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what’s in a name? Joint Bone Spine. 2012;79(6):534–535.
  • Wendling D, Claudepierre P, Prati C, et al. Spondyloarthritis: A concept or a disease? Joint Bone Spine. 2015 Jul 7. pii: S1297-319X(15)00129-3. DOI:10.1016/j.jbspin.2015.06.006. [Epub ahead of print].
  • Rudwaleit M, van der Heijde D, Landewé R, et al. The assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
  • Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904.
  • Wendling D, Lukas C, Paccou J, et al. Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis. Joint Bone Spine. 2014;81(1):6–14.
  • Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015;7:CD010952. [Epub ahead of print].
  • Braun J, Baraliakos X, Heldmann F, et al. Tumor necrosis factor alpha antagonists in the treatment of axial spondyloarthritis. Expert Opin Investig Drugs. 2014;23(5):647–659.
  • Maxwell LJ, Zochling J, Boonen A, et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468. DOI:10.1002/14651858.CD005468.pub2.
  • Maneiro JR, Souto A, Salgado E, et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open. 2015;1:e000017. DOI:10.1136/rmdopen-2014-000017.
  • Callhoff J, Sieper J, Weiß A, et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74(6):1241–1248.
  • Molto A, Granger B, Wendling D, et al. Non-steroidal anti-inflammatory drug-sparing effect of tumor necrosis alpha inhibitors in early axial spondyloarthritis: results from the DESIR cohort. Arthritis Rheumatol. 2015 Jun 24. DOI:10.1002/art.39208. [Epub ahead of print].
  • Gaujoux-Viala C, Fautrel B. Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review. Pharmacoeconomics. 2012;30(12):1145–1156.
  • Van den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol. 2014;28(5):819–827.
  • Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16.
  • Wendling D. Treating to target in axial spondyloarthritis: defining the target and the arrow. Expert Rev Clin Immunol. 2015;11(6):691–693.
  • Braun J, Kiltz U, Sarholz M, et al. Monitoring ankylosing spondylitis: clinically useful markers and prediction of clinical outcomes. Expert Rev Clin Immunol. 2015;11(8):935–946.
  • Wendling D, Guillot X, Prati C. The IL-23/Th 17 pathway in spondyloarthritis: the royal road? Joint Bone Spine. 2015;82(1):1–4.
  • Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. Nat Rev Rheumatol. 2015;11(7):415–429.

•An extensive review of the IL-23/Th17 axis in arthritis and spondyloarthritis.

  • Wendling D, Vuitton L, Koch S, et al. Spondyloarthritis and the gut: a new look. Joint Bone Spine. 2015;82(2):77–79.
  • Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069–1076.
  • Sherlock JP, Buckley CD, Cua DJ. The critical role of interleukin-23 in spondyloarthropathy. Mol Immunol. 2014;57(1):38–43.
  • Ciccia F, Guggino G, Rizzo A, et al. Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis. Ann Rheum Dis. 2015 Apr 22. pii: annrheumdis-2014-206323. DOI:10.1136/annrheumdis-2014-206323. [Epub ahead of print].
  • Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108–1110.
  • Song IH, Heldmann F, Rudwaleit M, et al. Different response to rituximab in tumornecrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum. 2010;62:1290–1297.
  • Wendling D, Dougados M, Berenbaum F, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol. 2012;39(12):2327–2331.
  • Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73(1):95–100.
  • Sieper J, Braun J, Kay J, et al. Sarilumab for the treatment of ankylosing spondylitis: results of a phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis. 2015;74(6):1051–1057.
  • Baeten D, Baraliakos X, Braun J, et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2013;382(9906):1705–1713.

••First controlled, proof of concept, of the efficacy of anti-IL-17A in ankylosing spondylitis.

  • Baraliakos X, Borah B, Braun J, et al. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study. Ann Rheum Dis. 2015 Aug 6. pii: annrheumdis-2015-207544. DOI:10.1136/annrheumdis-2015-207544. [Epub ahead of print].
  • Baeten DL, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52-week phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Arthritis Rheumatol. 2014;66(Suppl):S360.
  • Sieper J, Braun J, Baraliakos X, et al. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Arthritis Rheumatol. 2014;66(Suppl):S232.
  • Poddubnyy D, Hermann KG, Callhoff J, et al. Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis. 2014;73(5):817–823.

•First study evaluating anti-IL-12/23 in ankylosing spondylitis.

  • Novartis Pharmaceuticals. 16-Week efficacy and 3-year safety, tolerability and efficacy of secukinumab in active ankylosing spondylitis patients (MEASURE 3). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02008916. NLM Identifier: NCT02008916.
  • Novartis Pharmaceuticals. 16-Week efficacy and 2-year safety, tolerability and efficacy of secukinumab in participants with active ankylosing spondylitis (MEASURE4). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02159053. NLM Identifier: NCT02159053.
  • Eli Lilly and Company. Study of ixekizumab in participants with active ankylosing spondylitis (AS) (SPIRIT A1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01870284. NLM Identifier: NCT01870284.
  • Janssen Research & Development, LLC. A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti-TNF(Alpha) naive participants with active radiographic axial spondyloarthritis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02437162. NLM Identifier: NCT02437162.
  • Janssen Research & Development, LLC. A study to evaluate the efficacy and safety of ustekinumab in the treatment of anti-TNF(Alpha) refractory participants with active radiographic axial spondyloarthritis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02438787. NLM Identifier: NCT02438787.
  • Janssen Research & Development, LLC. An efficacy and safety study of ustekinumab in participants with active nonradiographic axial spondyloarthritis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT02407223. NLM Identifier: NCT02407223.
  • Pathan E, Abraham S, Van Rossen E, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis. 2013;72(9):1475–1480.
  • Celgene Corporation. Study of apremilast to treat subjects with active ankylosing spondylitis (POSTURE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01583374. NLM Identifier: NCT01583374.
  • Paramarta JE, Turina MC, Noordenbos T, et al. Targeting synovial mast cells in spondyloarthritis: a proof-of-concept study with nilotinib a tyrosine kinase inhibitor (OP0156). Ann Rheum Dis. 2014;73(Suppl2):120–121.
  • Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014;23(8):1067–1077.
  • Yamaoka K, Tanaka Y. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opin Pharmacother. 2014;15(1):103–113.
  • Pfizer. Dose-ranging study of tofacitinib in adults with active ankylosing spondylitis. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2015 Oct 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01786668. NLM Identifier: NCT01786668.
  • Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700.
  • Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370(24):2295–2306.
  • Bauer E, Lucier J, Furst DE. Brodalumab -an IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis. Expert Opin Biol Ther. 2015;15(6):883–893.
  • Fischer JA, Hueber AJ, Wilson S, et al. Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol. 2015;67(1):51–62.
  • Danese S, Panés J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology. 2014;147(5):981–989.
  • Asquith M, Elewaut D, Lin P, et al. The role of the gut and microbes inthe pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol. 2014;28(5):687–702.
  • Gill T, Asquith M, Rosenbaum JT, et al. The intestinal microbiome in spondyloarthritis. Curr Opin Rheumatol. 2015 Jul;27(4):319–325.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.